Document Detail


Biosimilars: recent developments.
MedLine Citation:
PMID:  17333516     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Biopharmaceuticals are recombinant protein drugs which are produced by biotechnology. The availability of such molecules has revolutionised the way we treat many diseases. However, the patents for many originator biopharmaceuticals are expiring, and a new generation of follow-on molecules, termed "biosimilars", are under development. Health care providers perceive biosimilars to be cheap replacements for originator drugs such as recombinant human erythropoietin and human growth hormone. However, concerns have been raised about the comparability of biosimilars with originator products especially in light of the complex manufacturing process required to produce biopharmaceuticals. The complexity of protein molecules renders it impossible to produce identical copies; this in turn raises questions on the safety of follow-on biosimilar products, particularly with respect to immunogenicity. This review briefly outlines the process of biopharmaceutical production, potential problems that can arise from their long-term use in patients, and the issues facing regulatory bodies as they look to institute guidelines for new biosimilar molecules.
Authors:
A Covic; M K Kuhlmann
Related Documents :
19767156 - Case histories in pharmaceutical risk management.
10294356 - Status of generic substitution: problematic drug classes reviewed.
20146636 - Are biosimilars really generics?
8724706 - A comparison of chlorhexidine, cetylpyridinium chloride, triclosan, and c31g mouthrinse...
6556076 - Law enforcement and drug trafficking money: recent developments in australian law and p...
24602126 - Inhibition of p-glycoprotein by psychotherapeutic drugs in a canine cell model.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-02-27
Journal Detail:
Title:  International urology and nephrology     Volume:  39     ISSN:  0301-1623     ISO Abbreviation:  Int Urol Nephrol     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-03     Completed Date:  2007-11-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0262521     Medline TA:  Int Urol Nephrol     Country:  Hungary    
Other Details:
Languages:  eng     Pagination:  261-6     Citation Subset:  IM    
Affiliation:
Dialysis and Transplantation Centre, C.I. Parhon University Hospital, Iasi 700503, Romania. acovic@xnet.ro
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Products* / biosynthesis,  immunology
Biotechnology / legislation & jurisprudence,  trends*
Drugs, Generic*
Humans
Legislation, Drug
Recombinant Proteins* / biosynthesis,  immunology
Chemical
Reg. No./Substance:
0/Biological Products; 0/Drugs, Generic; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Laparoscopic repair of vesicovaginal fistula.
Next Document:  Lunar phases and zodiac signs do not influence quality of radical cystectomy--a statistical analysis...